Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hologic’s 3-D Mammo: Reimbursement Timing Uncertain Following Approval

This article was originally published in The Gray Sheet

Executive Summary

Hologic says it is impossible to predict how long it will take to secure reimbursement for its newly approved Selenia Dimensions three-dimensional digital mammography system.

You may also be interested in...

FDA, Congress Look To Nationalize Breast Density Reporting Requirements, Now In 13 States

FDA hopes to finish drafting a proposed rule by early next year requiring mammography screening professionals to notify women and their physicians of dense breast tissue that may warrant further imaging follow-up with MRI and ultrasound. Meanwhile, a bill was recently introduced in Congress on the same topic.

Cleveland Clinic’s ‘Top 10’ Picks For 2013 Include Eight Device-Related Innovations

Renowned academic medical center unveils its annual ‘top 10’ list of medical innovations it anticipates will have a major impact on patient care within the next year, including eight that are device-related.

FDA Panel Supports Approval Of Hologic’s C-View Software For 3D Digital Mammography

PMA supplement approval endorsed by FDA’s Radiological Devices panel Oct. 24 would enable creation of 3D and 2D images from a single scan, thereby reducing radiation exposure compared to the current process.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts